What common side effects does Jakafi (ruxolitinib) cause?
Jakafi can cause several relatively common side effects, including effects on blood counts and infections. Reported common side effects include decreased red blood cells (anemia), decreased white blood cells (neutropenia/leukopenia), and decreased platelets (thrombocytopenia) [1].
It can also cause infection risk and symptoms such as upper respiratory infections, and other infection-related events are a known concern with Jakafi [1]. Other commonly reported side effects include dizziness, fatigue, and bruising [1].
Why do blood-count changes happen with Jakafi?
Jakafi works by inhibiting JAK signaling, which affects immune activity and blood cell production. That mechanism is why decreases in blood counts (anemia, low white blood cells, and low platelets) show up among common adverse effects [1].
Which side effects are most important to watch for?
Even when side effects are common, some require prompt medical attention:
- Signs of infection (fever, chills, sore throat, worsening cough), because lowered white blood cells and immune effects can increase infection risk [1].
- Symptoms of significant anemia (unusual tiredness, shortness of breath, weakness) [1].
- Easy bruising or bleeding that could relate to low platelets [1].
Do side effects differ by the condition Jakafi is used for?
The overall categories of common side effects are similar, but the frequency of specific problems can vary by indication and the patient’s baseline blood counts. Jakafi’s product information emphasizes blood-count decreases and infection risk among common effects across uses [1].
Are there ways doctors reduce or manage common Jakafi side effects?
Clinicians typically monitor complete blood counts and adjust the dose when blood counts drop or when patients develop adverse effects. This monitoring-and-adjustment approach targets the most common issues seen with Jakafi, especially anemia, neutropenia, and thrombocytopenia [1].
Sources
- FDA Prescribing Information – Jakafi (ruxolitinib)